Business Wire

Preliminary Results: Deutsche Post DHL Group Raises Guidance After Record Quarterly Earnings and Once Again Announces Corona Bonus for Employees

Share

Deutsche Post DHL Group (Symbol: DPW), the world’s leading logistics company, has today released preliminary results for the second quarter of 2021. Simultaneously, the outlook for the current financial year and for 2023 has been raised. Furthermore, an one-time corona bonus1 for approximately 550,000 employees worldwide has been decided. Preliminary operating profit (EBIT) for the second quarter has improved to record level with around EUR 2,075 million (Q2 2020: EUR 912 million) and has more than doubled compared to previous year. Against the backdrop of the excellent business performance, the Group has raised its EBIT outlook for 2021 to more than EUR 7.0 billion (so far: more than EUR 6.7 billion). The mid-term EBIT outlook for 2023 is now expected to be more than EUR 7.4 billion (so far: more than EUR 7.0 billion).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210707005615/en/

“The second quarter proved once again that global trade volume continues to recover and the e-commerce boom is sustainable – and we benefit strongly from both. All divisions continue to operate at full speed worldwide and achieve double-digit EBIT growth rates. We want to thank our employees who do fantastic work around the world and deserve another corona bonus“, said Frank Appel, CEO of Deutsche Post DHL Group.

Group grants once again one-time corona bonus of around EUR 200 million

As an appreciation for their tireless efforts during the pandemic the Group has decided to grant again a corona bonus of EUR 3002 to employees worldwide. This one-time payment is aimed at approximately 550,000 colleagues in all divisions and countries. Excluded are Executives. The corresponding expenses of around EUR 200 million will be booked in the third quarter 2021 and are already included in the updated earnings outlook for 2021.

All divisions achieved a significant jump in earnings

All divisions significantly exceeded the previous year's results. Network capacity utilization was constantly high in the second quarter 2021. B2C shipment volumes remained ahead of last year in all networks, while the recovery in the B2B businesses continued to gain momentum. At the same time the tight capacity situation both in Ocean and Air Freight markets remained unchanged.

Express: EBIT in the Express division reached around EUR 1,170 million in the second quarter 2021 compared to EUR 565 million in the previous year’s quarter.

Global Forwarding, Freight: EBIT in Global Forwarding, Freight stood at around EUR 315 million in the second quarter 2021, also clearly ahead of previous year’s result of EUR 190 million.

Supply Chain: EBIT at Supply Chain came in at around EUR 195 million in the second quarter 2021. It was at EUR 33 million in Q2 2020 in the initial stage of the pandemic.

eCommerce Solutions: eCommerce Solutions recorded EBIT of around EUR 115 million in the second quarter 2021, significantly above last year’s Q2 result which stood at EUR 1 million.

Post & Parcel Germany: EBIT in Post & Parcel Germany in the second quarter 2021 was around EUR 315 million (Q2 2020: EUR 264 million).

The positive business development is underpinned by a continued strong development of cash flow. Free cash flow in the second quarter 2021 amounted to more than EUR 800 million (Q2 2020: EUR 605 million). For the first half of 2021 free cash flow now stands at more than EUR 2.0 billion (H1 2020: EUR 196 million).

Earnings outlook raised in expectation of unchanged high shipment volumes and improved efficiency

In light of the ongoing earnings momentum the Group EBIT for 2021 is now expected to be more than EUR 7.0 billion (so far: more than EUR 6.7 billion). This includes additional expenses of around EUR 200 million for the one-time corona bonus. For the full year 2021, the Group now forecasts a free cash flow of more than EUR 3.2 billion (so far: more than EUR 3.0 billion). Gross capex in 2021 is expected to reach around EUR 3.9 billion (so far: around EUR 3.8 billion). The full year 2021 Group tax rate will now reach 28 percent, the upper end of the previously guided range of 26-28 percent.

Mid-term guidance for Group EBIT 2023 is now expected to be more than EUR 7.4 billion (previously: more than EUR 7.0 billion). The aggregated 2021-2023 guidance for free cash flow was left unchanged at around EUR 9.0 billion. The cumulative outlook for gross capex was also confirmed at around EUR 11.0 billion for the period 2021 to 2023.

The comprehensive disclosure for Q2/H1 2021 will be published as planned on August 5, 2021.

– End –

Deutsche Post DHL Group Deutsche Post DHL Group is the world’s leading logistics company. The Group connects people and markets and is an enabler of global trade. It aspires to be the first choice for customers, employees and investors worldwide. The Group contributes to the world through responsible business practice, corporate citizenship and environmental activities. By the year 2050, Deutsche Post DHL Group aims to achieve zero emissions logistics.

Deutsche Post DHL Group is home to two strong brands: Deutsche Post is Europe’s leading postal service. DHL offers a comprehensive range of international express, freight transport, and supply chain management services as well as e-commerce logistics solutions. Deutsche Post DHL Group employs approximately 570,000 people in over 220 countries and territories worldwide. The Group generated revenues of more than 66 billion Euros in 2020.

THE logistics company for the world.


1 EUR 300 per full-time employee
2 EUR 300 per full-time employee

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press contact
Deutsche Post DHL Group
Media Relations
Anita Gupta / Tobias Ender
Tel.: +49 228 182-9944
E-Mail: pressestelle@dpdhl.com
On the Internet: dpdhl.de/presse
Follow us: twitter.com/DeutschePostDHL

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Moody’s Analytics Earns #2 Overall Ranking in Chartis Research STORM505.8.2021 16:15:00 CEST | Press release

Moody’s Analytics is #2 in the inaugural Chartis Research STORM50 (Statistical Techniques, Optimization frameworks and Risk Models) ranking of the world’s leading providers of quantitative solutions for the financial industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210805005744/en/ Chartis’ STORM50 ranking measures the strength of solutions in quantitative modeling and software, assessing the level of innovation and the quality of the underlying computational infrastructure. The scoring is based on five criteria: breadth and coverage, impact, computational infrastructure, innovation, and strategy. In addition to the #2 ranking overall, Moody’s Analytics placed first in 14 of 55 categories, including Breadth & Coverage, Impact, Strategy, and Innovation, evidencing the depth of the company’s modeling expertise. “The inaugural Chartis Research STORM50 ranking highlights our ability to deliver an integrated view of risk

Ultivue Announces Co-Marketing Agreement with Fluidigm for Biomarker Imaging Solutions for Precision Medicine5.8.2021 15:30:00 CEST | Press release

Ultivue, Inc. and Fluidigm Corporation (Nasdaq:FLDM) today announced a co-marketing agreement in which the companies will offer customers a comprehensive portfolio of workflow solutions for biomarker discovery and drug development. Ultivue, a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation develops unique assays for use in multiplex immunofluorescence imaging and analysis. Its proprietary InSituPlex® technology is designed for fast and comprehensive exploration of biologically-relevant markers combined with same slide-H&E analysis in precious tissue samples. Fluidigm is a leader in high-parameter imaging for the clinical translational research and clinical testing markets. It’s Imaging Mass Cytometry™ (IMC™) technology is designed for highly multiplexed targeted interrogation of tissue sections for 40 or more protein markers in one scan, with distinct non-overlapping signals from element-labeled antibodies detected simultaneous

Andersen Global Strengthens Puerto Rican Coverage with Tax and Advisory Firm5.8.2021 15:30:00 CEST | Press release

Andersen Global adds dimension to its platform in Puerto Rico with the addition of collaborating firm AFS CPA Group LLC (AFS), solidifying its presence in the country with tax and legal coverage. AFS provides tax and advisory services to clients including individuals and small and large businesses, serving a variety of industries such as legal, medical, food and restaurants, apparel, marketing, technology, non-profit and homeowners associations. The firm, established in 2000 by Founder and Managing Partner Antonio Sécola, is based in Gurabo and offers tax, financial, investment and cash management services as well as outsourcing and payroll functions. “As an Arthur Andersen alumnus, I look forward to rejoining the culture and working with like-minded individuals who are committed to serving clients best-in-class solutions,” Antonio said. “Our firm is dedicated to providing the highest quality service, and this collaboration further supplements our ability to deliver seamless solutions

Precision for Medicine and Trialbee Partner to Advance Clinical Trials for Complex Therapies and Speed Shift Toward Precision Medicine5.8.2021 15:22:00 CEST | Press release

Clinical research organization Precision for Medicine and Trialbee, a patient matching and enrollment platform, are addressing complexities in clinical development through a new partnership that will accelerate the future of precision medicine. Trialbee’s advanced analytics will play a critical role in matching patients to trials conducted by Precision for Medicine and extending recruitment to a more diverse, targeted patient community for the development of complex, personalized medicine. The partnership expands Precision for Medicine’s ability to match patients who could benefit from life-saving therapies, especially those who could be a match for trials in oncology, rare and orphan diseases, including cell or gene therapy trials. Trialbee enables accurate and fast enrollment, improving the patient journey and helping to meet patient enrollment timelines. The Precision Site Network, which includes both academic and non-academic sites across North America, Europe, and Australia, can c

Loop Energy Enters Joint Market Development Agreement With Técnicas Reunidas to Accelerate the Commercialization of Hydrogen-Powered Vehicles5.8.2021 14:00:00 CEST | Press release

Loop Energy (TSX:LPEN), a developer and manufacturer of hydrogen fuel cell-based solutions, announces their joint market development agreement with Técnicas Reunidas (TR) – a global provider of services for investors in hydrogen infrastructure based in Madrid, Spain. Under this agreement, both parties will aim to secure future opportunities that require both TR’s hydrogen know-how and Loop Energy’s fuel cell technology. The initial scope of this joint market agreement focuses on providing hydrogen-based solutions to several key vertical markets: transport agencies, truck, transit and coach bus service fleets, materials handling, warehouse and port logistics including drayage, urban delivery services and stationary power applications. With the assistance of TR’s on-site production and supply equipment, creating hydrogen both via water electrolysis and steam reforming of natural gas, biogas or bioethanol, Loop will be able to provide more convenient and cost-effective hydrogen solutions

Moody's to Acquire RMS, Leader in Climate & Natural Disaster Risk5.8.2021 13:18:00 CEST | Press release

Moody's Corporation (NYSE: MCO) and RMS announced today that they have entered into a definitive agreement for Moody’s to acquire RMS, a leading global provider of climate and natural disaster risk modeling and analytics, for approximately $2.0 billion from Daily Mail and General Trust plc (LON: DMGT). The acquisition will immediately increase Moody’s insurance data and analytics business to nearly $500 million in revenue and will accelerate the development of the Company’s global integrated risk capabilities to address the next generation of risk assessment. With over 400 risk models covering 120 countries, RMS is the world’s leading provider of climate and natural disaster risk modeling serving the global property and casualty (P&C) insurance and reinsurance industries. For the fiscal year ending September 30, 2021, RMS is expected to generate revenue of approximately $320 million1 and adjusted operating income of approximately $55 million1. "Today’s leaders face a complex, interlink

Final Results from the Longest Hereditary Angioedema Study of Active Treatment Duration Conducted to Date Support the Sustained Safety and Efficacy of TAKHZYRO ® (lanadelumab) Injection for Long-Term Prevention of Hereditary Angioedema Attacks5.8.2021 13:00:00 CEST | Press release

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”) today announced the publication of the final results from the Phase 3 HELP (Hereditary Angioedema Long-term Prophylaxis) Study™ Open-label Extension (OLE) designed to evaluate the long-term safety (primary endpoint) and efficacy of TAKHZYRO® (lanadelumab) 300mg every two weeks for up to 2.5 years. The study results show that preventative treatment with TAKHZYRO markedly reduced the frequency of hereditary angioedema (HAE) attacks in patients 12 years of age and older who received treatment for a mean duration of almost 2.5 years (29.6 months; 8.2 standard deviation).1 The data were published online this month in the journal Allergy. Secondary endpoints of the study showed the mean (min;max) HAE attack rate observed in the study population (N=209) was reduced by 87.4 percent (-100; 852.8) overall versus baseline, and attacks requiring acute treatment (N=106) were reduced by 93.4 percent (-100; -52.8).1 Reductions were

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom